Lisata Therapeutics adds Jeffrey Farrow to board of directors

Lisata Therapeutics' (LSTA) subsidiary Marea Therapeutics dosed the first patient in a Phase 2 trial for MAR002, a treatment for acromegaly. The trial aims to enroll 72 participants, with primary endpoint measuring IGF-1 reduction after 10 weeks. MAR002 could offer less frequent dosing than current treatments. Lisata's valuation may be impacted by clinical milestones, according to InvestingPro.

Lisata Therapeutics' subsidiary Marea began a Phase 2 trial for MAR002, a treatment for acromegaly, after Phase 1 data showed IGF-1 suppression and supported biweekly dosing. The trial follows positive early-stage results and aims to further evaluate the drug's efficacy and safety.

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.

Lisata Therapeutics' subsidiary Marea Therapeutics dosed the first patient in a Phase 2 trial for MAR002, an antibody therapy for acromegaly. The trial aims to enroll 72 participants, with primary endpoint being IGF-1 reduction after 10 weeks. MAR002 may offer less frequent dosing than current treatments, according to the company.

Lisata Therapeutics, Inc. raised $352 million in a securities offering. The company, incorporated in Delaware, is involved in the healthcare industry. The offering was filed with the SEC under Rule 506(b).

Lisata Therapeutics (LSTA) acquired Marea Therapeutics and secured $225M in financing, diluting legacy shareholders to 2.39% ownership. The funds will support operations into 2028, covering clinical trials for severe hypertriglyceridemia and acromegaly. Success could attract partnerships or improve future financing terms, but risks include clinical trial failures and cash settlement obligations.